Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis

Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis

Authors

  • Lorenzo Mantovani Research Centre on Public Health (CESP), University of Milan – Bicocca, Monza, Italy
  • Paolo Angelo Cortesi Research Centre on Public Health (CESP), University of Milan – Bicocca, Monza, Italy
  • Michele Molina Biogen Italia, Milan, Italy
  • Laura Santoni Biogen Italia, Milan, Italy
  • Luca Prosperini Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy

DOI:

https://doi.org/10.7175/fe.v25i1.1568

Downloads

Published

2024-12-17

How to Cite

Mantovani, L., Cortesi, P. A., Molina, M., Santoni, L., & Prosperini, L. (2024). Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis. Farmeconomia. Health Economics and Therapeutic Pathways, 25(1). https://doi.org/10.7175/fe.v25i1.1568

Issue

Section

Letter to the Editor

Most read articles by the same author(s)

1 2 > >> 
Loading...